Moderna (MRNA) to Release Earnings on Friday

Moderna (NASDAQ:MRNA - Get Free Report) is expected to be issuing its Q4 2024 quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.86) per share and revenue of $951.09 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Moderna Stock Up 3.4 %

NASDAQ:MRNA traded up $1.07 during trading hours on Friday, hitting $32.99. 25,297,536 shares of the company traded hands, compared to its average volume of 12,567,232. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm's 50-day simple moving average is $38.86 and its 200-day simple moving average is $54.70. Moderna has a one year low of $29.25 and a one year high of $170.47. The company has a market cap of $12.70 billion, a PE ratio of -5.67 and a beta of 1.59.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several recent analyst reports. Bank of America dropped their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Wednesday, January 15th. JPMorgan Chase & Co. lowered their target price on Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research note on Tuesday, November 26th. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research note on Friday, November 8th. Finally, Evercore ISI lowered their target price on Moderna from $60.00 to $50.00 and set an "in-line" rating on the stock in a research note on Monday, January 27th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $66.89.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 2,664 shares of company stock valued at $115,210 in the last quarter. 15.70% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.